181867-19-6

Basic information

• Product Name: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)
• Synonyms: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI);1-Methyl-1H-benzo[d]imidazole-6-carbaldehyde;1H-Benzimidazole-6-carboxaldehyde, 1-methyl-;1-Methyl-1H-1,3-benzodiazole-6-carbaldehyde;3-methylbenzimidazole-5-carbaldehyde
• CAS NO: 181867-19-6
• Molecular Formula: C₉H₈N₂O
• Molecular Weight: 160.17262
• Product Categories: BENZIMIDAZOLE;ALDEHYDE
• Mol File: 181867-19-6.mol

Chemical Properties

• Boiling Point: 336.9 °C at 760 mmHg
• Flash Point: 157.5 °C
• Appearance: /
• Density: 1.21 g/cm³
• Vapor Pressure: 0.000109mmHg at 25°C
• Refractive Index: 1.622
• PKA: 4.41±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)(181867-19-6)
• EPA Substance Registry System: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)(181867-19-6)

Safety Data

• Hazardous Substances Data: 181867-19-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole-6-carboxaldehyde, 1-methyl(9CI) is used as a key intermediate in the synthesis of various drugs, particularly in the development of anticancer and antiviral medications. Its unique structure and potential biological activities make it a valuable component in the creation of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Benzimidazole-6-carboxaldehyde, 1-methyl(9CI) serves as a building block for the preparation of other chemical compounds. Its versatile properties allow it to be incorporated into a wide range of molecules, contributing to the advancement of chemical research and the development of new materials.
Due to its diverse applications and significance in both research and industrial sectors, 1H-Benzimidazole-6-carboxaldehyde, 1-methyl(9CI) is recognized as an important and valuable chemical compound.

InChI:InChI=1/C9H8N2O/c1-11-6-10-8-3-2-7(5-12)4-9(8)11/h2-6H,1H3

Upstream product

• 7790-28-5 sodium periodate 
• 813449-02-4 1-methyl-6-vinyl-benzimidazole 
• 68-12-2 N,N-dimethyl-formamide 
• 53484-16-5 6-bromo-1-methyl-1H-benzo[d]imidazole 
• 177476-75-4 3-methoxy-4-nitrobenzoinitrile 
• 92241-87-7 3-methoxy-4-nitrobenzamide 
• 64910-48-1 3-N-(methylamino)-4-nitrobenzonitrile 
• 64910-49-2 4-amino-3-(methylamino)benzonitrile 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 106429-29-2 5-(hydroxymethyl)-benzimidazole 
• 15788-16-6 5-benzimidazolecarboxylic acid 
• 58442-17-4 1H-benzo[d]imidazole-5-carbaldehyde 
• 74-88-4 methyl iodide 
• 53484-14-3 3-methyl-3H-benzoimidazole-5-carbonitrile 

Relevant articles and documents

NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES

Provided are novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases. Specifically, provided are the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, prepa

Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells

Resistance to combretastatin A-4 is mediated by metabolic modification of the phenolic hydroxyl and ether groups of the 3-hydroxy-4-methoxyphenyl (B ring). Replacement of the B ring of combretastatin A-4 by a N-methyl-5-indolyl reduces tubulin polymerization inhibition (TPI) and cytotoxicity against human cancer cell lines but cyano, methoxycarbonyl, formyl, and hydroxyiminomethyl substitutions at the indole 3-position restores potent TPI and cytotoxicity against sensitive human cancer cell lines. These highly potent substituted derivatives displayed low nanomolar cytotoxicity against several human cancer cell lines due to tubulin inhibition, as shown by cell cycle analysis, confocal microscopy, and tubulin polymerization inhibitory activity studies, and promoted cell killing mediated by caspase-3 activation. Binding at the colchicine site was suggested by molecular modeling studies. Substituted combretastatins displayed higher potencies than the isomeric isocombretastatins and the highest potencies were achieved for the hydroxyiminomethyl (21) and cyano (23) groups, with TPI values in the submicromolar range and cytotoxicities in the nanomolar and subnanomolar range. Dose-response and time-course studies showed that drug concentrations as low as 1 nM (23) or 10 nM (21) led to a complete G2/M cell cycle arrest after 15 h treatment followed by a high apoptosis-like cell response after 48–72 h treatment. The P-glycoprotein antagonist verapamil increased 21 and 23 cytotoxicity to IC50 values of 10?10 M, and highly potentiated the cytotoxic activity in 100-fold of the CHO derivative (17), in A-549 human non-small cell lung cancer cells. The cyano substituted indolecombretastatin 23 is by itself highly potent against rather resistant HT-29 and A-549 cell lines. A 3,4,5-trimethoxyphenyl ring always afforded more potent derivatives than a 2,3,4-trimethoxyphenyl ring.

IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE

The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, ne

NOVEL CHEMICAL COMPOUNDS

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.

4- (HETEROCYCLYL- FUSED PHENYL)- 3- (PHENYL OR PYRID -2- YL) PYRAZOLES AS INHIBITORS OF THE ALK-5- RECEPTOR

The invention relates to novel pyrazole derivatives which are inhibitors of the transforming growth factor, ("TGF")-β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase ("ALK")-5 receptor, m